Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An in vitro study

Li, Fang; Li, Jianing; Wen, Xuejun; Zhou, Shenghu; Tong, Xiaowen; Su, Pingping; Li, Hong; Shi, Donglu

doi:10.1016/j.msec.2009.07.001

Cited by 84 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…62 Paclitaxel chitosan nanoparticles had a high encapsulation rate of 94.0% ± 16.73% with sustained-release effect. 63 Cell toxicity testing showed that paclitaxel-chitosan nanoparticles had a higher toxicity than that of paclitaxel alone, and with a higher cell uptake rate. Using an evaporation method of composite microemulsion …”

Section: Carrier Of Anticancer Chemical Drugsmentioning

confidence: 99%

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

258

124

View full text Add to dashboard Cite

Chitosan nanoparticles are good drug carriers because of their good biocompatibility and biodegradability, and can be readily modified. As a new drug delivery system, they have attracted increasing attention for their wide applications in, for example, loading protein drugs, gene drugs, and anticancer chemical drugs, and via various routes of administration including oral, nasal, intravenous, and ocular. This paper reviews published research on chitosan nanoparticles, including its preparation methods, characteristics, modification, in vivo metabolic processes, and applications.

show abstract

Section: Carrier Of Anticancer Chemical Drugsmentioning

confidence: 99%

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

258

124

View full text Add to dashboard Cite

show abstract

“…9–10 LbL-coated particles of these drugs are of interest as promising intravenously injectable forms that are aqua-based with a particle diameter less than 200 nm and good colloidal stability in phosphate buffered saline (PBS) and biological fluids (blood serum). Newly developing drug nano-formulations must comply with the following criteria: the content of the drugs in a capsule has to exceed 30 wt % and drug concentration in a stable nanocolloid for injection has to be above 2 mg/mL.…”

Section: Introductionmentioning

confidence: 99%

Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes

et al. 2012

View full text Add to dashboard Cite

150–200 nm diameter capsules containing 60–70 wt % of poorly soluble drugs, paclitaxel and camptothecin, were produced by layer-by-layer (LbL) assembly on drug nanocores in a solution containing uncharged stabilizers. Optimization of capsule shell architecture and thickness allowed for concentrated (3–5 mg/mL) colloids that are stable in isotonic salt buffers. Nanoparticle aggregation during the washless LbL-assembly was prevented by using low molecular weight block-copolymers of poly(amino acids) (poly-L-lysine and poly-L-glutamic acid) with polyethylene glycol (PEG) in combination with heparin and bovine serum albumin at every bilayer building step. Minimal amounts of the polyelectrolytes were used to recharge the surface of nanoparticles in this non-washing LbL process. Such PEGylated shells resulted in drug nanocapsules with high colloidal stability in PBS buffer and increased protein adhesion resistance. The washless LbL polyelectrolyte nanocapsule assembly process, colloidal stability and nanoparticle morphology were monitored by dynamic light scattering and electrophoretic mobility measurements, UV-vis spectroscopy, TEM, SEM and laser confocal microscopy imaging.

show abstract

“…Most of the non-steroidal anti-inflammatory drugs that commonly used to treat RA have a low solubility in gastric fluid but have a good solubility in intestine fluid [40]. Many researchers have proved the ability of nanoparticles in improving the bioavailability of drugs with low solubility [41] while delivered via oral [42], transdermal [43], intravenous [44], and pulmonary [45,46]. On the other hand, the improvement of the amount of drugs in systemic will increase the risk of side effects occurrence until the possibility of achieving toxic level [47].…”

Section: Nanoparticle Challenge As Novel Treatment Of Rheumatoid Arthmentioning

confidence: 99%

Rheumatoid arthritis and the challenge of using nanoparticles for its treatment

et al. 2018

View full text Add to dashboard Cite

Abstract. Rheumatoid arthritis is the most common autoimmune disease that affects the joints. The cause of the disease is unknown, many studies proposed hypothesis about the etiology of rheumatoid arthritis. The clinical manifestations of arthritis are different in each patients. In addition, the development of the medication is still continue to achieve the most effective role with less side effect. Nanoparticles may be the answer to this problem, since they have been widely used to improve the pharmacokinetic and pharmacodynamics of rheumatoid arthritis drugs. Using nanoparticles-tagged folate or PEG to deliver rheumatoid arthritis drugs may increase the specificity of the drugs to the target and consequently, may decrease the side effects of the drugs. The purpose of this review is to summarize the etiology, clinical manifestation and highlighting the use of nanoparticles in rheumatoid arthritis treatment.

show abstract

Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An in vitro study

Cited by 84 publications

References 15 publications

Recent advances of chitosan nanoparticles as drug carriers

Recent advances of chitosan nanoparticles as drug carriers

Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes

Rheumatoid arthritis and the challenge of using nanoparticles for its treatment

Contact Info

Product

Resources

About